英特转债

Search documents
英特集团: 2025年第二季度可转换公司债券转股情况公告
Zheng Quan Zhi Xing· 2025-07-02 16:06
证券代码:000411 证券简称:英特集团 公告编号:2025-035 特别提示: 英特转债(债券代码:127028)转股期为 2021 年 7 月 12 日至 2027 年 1 月 4 日,截 至目前,转股价格为人民币 9.30 元/股。 根据《深圳证券交易所股票上市规则》 《深圳证券交易所可转换公司债券业务实施细则》 的有关规定,浙江英特集团股份有限公司(以下简称"英特集团"或"公司")现将 2025 年第 二季度可转换公司债券(以下简称"可转债")转股及公司股份变动情况公告如下: 一、可转债发行上市基本情况 债券代码:127028 债券简称:英特转债 浙江英特集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导 性陈述或重大遗漏。 经中国证券监督管理委员会"证监许可20203159 号"文核准,公司于 2021 年 1 月 5 日 公开发行了 600 万张可转债,每张面值 100 元,发行总额 60,000 万元,期限 6 年。 经深圳证券交易所(以下简称"深交所")同意,公司发行的 6 亿元可转债自 2021 年 3 月 10 日起在深交所上市交易,债券简称为 ...
英特集团: 2020年浙江英特集团股份有限公司公开发行可转换公司债券定期跟踪评级报告
Zheng Quan Zhi Xing· 2025-06-23 12:53
Core Viewpoint - The company, Zhejiang Yintai Group, is a leading player in the pharmaceutical distribution industry in Zhejiang Province, with a strong market position and expanding business operations despite increasing competition and regulatory pressures in the healthcare sector [1][2]. Group 1: Company Overview - Zhejiang Yintai Group is recognized as a top pharmaceutical distribution enterprise in Zhejiang Province, covering all levels of public hospitals and private pharmacies [1][2]. - The company has achieved steady growth in its business scale and market share, particularly in the pharmaceutical wholesale sector, which contributes approximately 90% of its revenue [5][6]. - The company has diversified its operations by developing new retail and medical device businesses, enhancing its revenue streams [5][7]. Group 2: Financial Performance - The company reported revenues of CNY 306.19 billion, CNY 320.52 billion, CNY 333.52 billion, and CNY 84.37 billion for the years 2022, 2023, 2024, and the first quarter of 2025, respectively, with year-on-year growth rates of 14.55%, 4.68%, 4.05%, and -1.87% [5][4]. - The pharmaceutical wholesale business generated revenues of CNY 282.40 billion, CNY 290.88 billion, CNY 299.33 billion, and CNY 75.72 billion during the same periods, with growth rates of 15.23%, 0.49%, 2.90%, and a decline of 3.57% [5][7]. - The company’s retail business has also seen significant growth, with revenues of CNY 22.34 billion, CNY 27.52 billion, CNY 31.78 billion, and CNY 8.37 billion from 2022 to the first quarter of 2025 [7]. Group 3: Market Challenges - The pharmaceutical industry is facing tightening policies and increased competition, which have compressed profit margins in the distribution sector [2][3]. - The company is experiencing pressure from national drug procurement policies that have led to price reductions, necessitating the introduction of innovative products to maintain profitability [6][7]. - The company must manage liquidity risks due to the nature of the pharmaceutical distribution business, which involves significant receivables and longer payment cycles [2][3]. Group 4: Future Outlook - The company is expected to maintain its credit quality in the coming months, provided it continues to expand its business scale and enhance its capital strength [2][3]. - The ongoing development of new retail formats and the integration of online and offline sales channels are anticipated to support future revenue growth [7][8]. - The company is investing in the Zhejiang Yintai Shitang Pharmaceutical Industrial Park project, which aims to enhance its logistics and operational capabilities [9][10].
英特集团: 关于英特转债转股价格调整的公告
Zheng Quan Zhi Xing· 2025-05-27 11:35
证券代码:000411 证券简称:英特集团 公告编号:2025-031 债券代码:127028 债券简称:英特转债 浙江英特集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导 性陈述或重大遗漏。 根据《浙江英特集团股份有限公司公开发行可转换公司债券募集说明书》(以下简称 "《募集说明书》")的可转换公司债券发行方案,在本次发行之后,若公司发生派送股票 股利、转增股本、增发新股(不包括因本次发行的可转换公司债券转股而增加的股本)、配 股以及派发现金股利等情况,将按下述公式进行转股价格的调整(保留小数点后两位,最后 一位四舍五入) 派送股票股利或转增股本:P1=P0/(1+n) 增发新股或配股:P1=(P0+A×k)/(1+k); 上述两项同时进行:P1=(P0+A×k)/(1+n+k) 派送现金股利:P1=P0-D; 上述三项同时进行:P1=(P0-D+A×k)/(1+n+k) 其中:P1 为调整后转股价,P0 为调整前转股价,n 为送股或转增股本率,A 为增发新 股价或配股价,k 为增发新股或配股率,D 为每股派送现金股利。 当公司出现上述股份和/或股东权益变化情况 ...
英特集团: 关于实施权益分派期间英特转债暂停转股的公告
Zheng Quan Zhi Xing· 2025-05-22 11:10
Core Viewpoint - Zhejiang Yinte Group Co., Ltd. plans to implement a profit distribution scheme for the year 2024, maintaining the total distribution amount unchanged, which will lead to a temporary suspension of the conversion of its convertible bonds, Yinte Convertible Bonds (code: 127028) [1][2] Group 1 - The company will hold the 2024 annual general meeting on May 16, 2025, to review the profit distribution proposal [1] - The convertible bonds will be suspended from conversion starting from May 26, 2025, until the record date for the profit distribution [1][2] - The company assures that the information disclosed is true, accurate, and complete, with no false records or significant omissions [1] Group 2 - During the suspension period, the Yinte Convertible Bonds will continue to trade normally [2] - The adjustment of the conversion price will occur in the event of stock dividends, capital increases, new share issuances, or cash dividends, following specific formulas for calculation [2][3] - The company will announce any adjustments to the conversion price and the suspension period through designated media [3]